Next, we tested 20F2 in the first round PDX models established with AML patient samples representing three subsets of AML based on TMIGD2 expression, including CD34+TMIGD2low (Pt#31, <10% TMIGD2+ cells), CD34+TMIGD2high (Pt#28, >80% TMIGD2+ cells) and CD34-TMIGD2+ (Pt#21, 37% TMIGD2+ cells). The gene discussed is TMIGD2; the disease is acute myeloid leukemia.